B. Rive - Janssen EMEA, Paris, France

基本信息

浏览量：2

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 52 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Disease-specific Quality of Life with Esketamine Nasal Spray Versus Quetiapine Extended Release in Treatment Resistant Depression: Results from ESCAPE-TRD

A.H. Young, O. Blomqvist, J. Diels, A. Fagiolini,Y. Godinov, P.M. LLorca,S. Mulhern-Haughey, C. Normann,B. Rive, A.J. Oliveira-Maia

Neuroscience Applied (2024): 104962

引用0浏览0引用

Esketamine Nasal Spray Shows Greater Improvement in Health-Related Quality of Life over 32 Weeks Versus Quetiapine Extended Release in Patients with Treatment Resistant Depression

A. H. Young,B. T. Baune,N. Cardoner,R. Frey,T. Ito,Y. Kambarov, A. Lacerda,B. Rive,C. von Holt,A. J. Oliveira-Maia

EUROPEAN PSYCHIATRY (2024): S363-S365

引用0浏览0引用

Duration and Impact of Adverse Events with Esketamine Nasal Spray and Quetiapine Extended Release in the ESCAPE-TRD Phase IIIb Trial

E. Vieta,P.M. Llorca,A.J. Oliveira-Maia, L. Häggström, W. Cubała, J. Buyze,Y. Godinov,B. Rive,A. Reif

Neuroscience Applied (2023): 102949

引用0浏览0引用

Remission/response with Esketamine Nasal Spray Versus Quetiapine Extended Release in Treatment Resistant Depression Using the Patient Health Questionnaire

A. Young, R. Frey,R.E. Nielsen,A.E. Anıl Yağcıoğlu, L. Häggström, P.M. Llorca, I. Bitter,S. Mulhern-Haughey,B. Rive,Y. Godinov

Neuroscience Applied (2023): 102947

引用0浏览0引用

Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial

A. Reif,A. E. Anil Yagcioglu, A. Luts,T. Messer,R. Nielsen, J. Buyze,T. Ito,Y. Kambarov,S. Mulhern Haughey,B. Rive,I. Usankova,C. von Holt,Y. Godinov

European Psychiatry (2023): S90-S91

引用0浏览0引用

Esketamine Nasal Spray Improves Rate and Time to Remission Versus Quetiapine Extended Release in Subgroups of Patients with Treatment Resistant Depression and Two or Three Plus Prior Treatment Failures: Results from ESCAPE-TRD, a Randomised Phase IIIb Trial

A. H. Young,W. J. Cubala,R. E. Nielsen, A. Popova,T. Ito,S. Mulhern-Haughey, N. Pirotte,B. Rive,P. Thilakarathne,I. Usankova,Y. Godinov

BJPsych Openno. S1 (2023): S75-S75

引用0浏览0引用

CO151 Estimating the Benefit of Esketamine Nasal Spray Versus Real-World Treatment on Patient-Reported Functional Remission: Results from the Iceberg Study

A. Oliveira-Maia,B. Rive,J. Morrens,Y. Godinov,S. Mulhern-Haughey

Value in Health（2022）

引用0浏览0引用

Study Design of ESCAPE-TRD, a Long-Term, Comparative, Randomised Phase IIIb Clinical Trial of Esketamine Nasal Spray in Treatment Resistant Depression

A. Reif,T. Messer, P. Eckhard,K. Heerlein,R. Milz, K. Olbrich,B. Rive,G. Van Dooren,C. von Holt, R. Wapenaar,Y. Godinov

Neuroscience Applied (2022): 100638-100638

引用0浏览0引用

P.0226 Indirect Comparison Estimating the Benefit of Esketamine Compared to Distinct Real-World Treatment Strategies for Treatment Resistant Depression in General Psychiatry

B. Rive,A. J. Oliveira-Maia, B. Falissard,S. Mulhern Haughey, S. Barbreau,Y. Godinov,J. Morrens

European Neuropsychopharmacology (2021): S163-S165

引用0浏览0引用

P.0225 Indirect Comparison Estimating the Benefit of Esketamine Compared to Real-World Treatment of Treatment Resistant Depression in General Psychiatry: Preliminary Analysis

J. Morrens,A. J. Oliveira-Maia, B. Falissard,S. Mulhern Haughey, S. Barbreau,Y. Godinov,B. Rive

European Neuropsychopharmacology (2021): S162-S163

引用1浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn